Treating macular edema secondary to retinal vein occlusion with suprachoroidal injection of triamcinolone acetonide using custom made needle

Marashi, Ameen

doi:10.15406/aovs.2018.08.00321

Cited by 2 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 This speculation was further demonstrated by numerous preclinical and clinical investigations through microinjectors, which has been displayed to give a safe, negligibly intrusive, and solid technique for focusing on SCS. 22 Likewise, broadened term of activity and alluring pharmacokinetic properties have been accounted for little atom suspensions including Triamcinolone Acetonide (TA), with the possibility to decrease the weight of treatment. 23 A case report by Marashi A, also reported visual acuity improvement from baseline of 20/100 to 20/30 at 8 weeks, with significant decrease in macular thickness from baseline without any complications.…”

Section: Discussionmentioning

confidence: 99%

“…23 A case report by Marashi A, also reported visual acuity improvement from baseline of 20/100 to 20/30 at 8 weeks, with significant decrease in macular thickness from baseline without any complications. 22 Study recommends that suprachoroidal injection of TA could be an adequate, mediocre, and minimal expense restorative option for the treatment of CRVO related macular edema. This was additionally affirmed in our review.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema

Salahuddin¹,

Jan²,

Mahsood³

et al. 2023

pak J Ophthalmol

View full text Add to dashboard Cite

Purpose: To determine the outcomes of intravitreal Bevacizumab 1.25 mg in 0.05 ml combined with supra-choroidal triamcinolone acetonide 0.05 ml in terms of safety and efficacy, while treating macular edema associated with central retinal vein occlusion (CRVO). Study Design: Interventional case series. Place and Duration of Study: This study was conducted at ophthalmology department of Hayatabad medical complex, Peshawar from July 2021 to December 2021. Methods: Total 34 patients of CRVO with macular edema were included in the study. After complete ocular examination each patient received one injection of intravitreal bevacizumab (1.25 mg/0.05 ml) along with supra-choroidal triamcinolone acetonide (2 mg/0.05 ml), followed by similar monthly injections for two months. Visual acuity and central macular thickness and intra-ocular pressure (IOP) were assessed at presentation and then monthly for 3 months. Visual acuity was measured in Log-MAR, central foveal thickness on SD-OCT and IOP was measured with Goldmann Applanation Tonometer. The data was analyzed using SPSS version 24. For comparison of means, the paired-t test was used. A significance level of <0.05 was set for significance. Results: There were 22 (64.7%) males and 12 (35.5%) females. Mean age of the patients was 53.18 ± 13.39 years. Central foveal thickness decreased significantly at 3 months post treatment (p ˂ 0.001). Visual acuity also significantly increased from presentation to 3rd month post treatment (p ˂ 0.001), and the intra-ocular pressure remained within normal range from presentation to 3rd month post treatment. Conclusion: Both supra-choroidal triamcinolone acetonide and intravitreal bevacizumab are safe and effective in the treatment of macular edema secondary to CRVO.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema

Salahuddin¹,

Jan²,

Mahsood³

et al. 2023

pak J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Vernier callipers were used to determine the length of the 30G needle extruding out of the stopper ( Figure 1 ). 15 …”

Section: Methodsmentioning

confidence: 99%

“…The bevel of the 30G needle was kept away from the limbus and was inserted into the sclera perpendicularly until the stopper touched the conjunctiva ( Figure 2 ). 15 The drug was then injected into the suprachoroidal space and the needle was withdrawn obliquely to prevent reflux.…”

Section: Methodsmentioning

confidence: 99%

Suprachoroidal injection of triamcinolone acetonide using a custom-made needle to treat diabetic macular edema post pars plana vitrectomy: a case series

Marashi¹,

Zazo

2022

J Int Med Res

Self Cite

View full text Add to dashboard Cite

Objective Diabetic macular edema (DME), the most common cause of diabetes-related visual impairment, may occur following pars plana vitrectomy (PPV) to manage proliferative diabetic retinopathy complications. This retrospective single-centre case series evaluated the efficacy and safety of injecting 4 mg/0.1 ml triamcinolone into the suprachoroidal space using a custom-made needle to treat DME post PPV. Methods Data regarding central macular thickness (CMT) using spectral domain-optical coherence tomography and best-corrected visual acuity (by Snellen chart) at baseline (pre-injection), and at 1, 4, and 8 weeks following injection were analysed, along with intraocular pressure (IOP), cataract progression, and ocular safety. Results Eleven eyes in 10 patients received 11 suprachoroidal injections. Vision improvement was noted (0.75 log minimum angle of resolution (MAR) at baseline to 0.40 log MAR after treatment). CMT reduced significantly from 456.45 ± 113.42 μm at baseline to 247.63 ± 53.40 μm at 8 weeks following injection. No rise in IOP, or cataract development in the single treated phakic eye, was observed during 8 weeks of follow-up. Conclusion Suprachoroidal injection of triamcinolone using a custom-made needle to treat DME post PPV shows promising results with acceptable safety outcomes. Large clinical trials with longer follow-up are needed to evaluate this treatment option for countries with limited health-care resources.

show abstract

Treating macular edema secondary to retinal vein occlusion with suprachoroidal injection of triamcinolone acetonide using custom made needle

Cited by 2 publications

References 10 publications

Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema

Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema

Suprachoroidal injection of triamcinolone acetonide using a custom-made needle to treat diabetic macular edema post pars plana vitrectomy: a case series

Contact Info

Product

Resources

About